Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDCA challenge study of the bile salt-FXR-FGF19 axis in quiescent Crohn's colitis
NL-OMON35367Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of chenodeoxycholic acid in Crohn's disease (2 cohorts), sponsored by University Medical Center Utrecht. Primary endpoint: Change in fasting plasma FGF19 after 8 days of CDCA. Started Jan 2010; status: active, not recruiting.
02
Drugs
chenodeoxycholic acid
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON35367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35367.